



Date: October 19, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex Bandra (East) <u>Mumbai - 400 051</u> <i>Stock Code : INDOCO-EQ</i>	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai - 400 001</u> <i>Stock Code : 532612</i>
---	---

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Indoco Remedies Limited Goa Plant I

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a pre-approval inspection ("PAI") was conducted by the United States Food and Drug Administration ("USFDA") at the at the Company's Solid Oral Formulation facility (Plant I) located at Goa ("Facility") from October 12, 2023 to October 18, 2023.

The pre-approval inspection was conducted for two drug product applications (ANDAs) filed from this Facility. The USFDA has issued 'four observations' in Form 483 at the end of the pre-approval inspection.

The Company is committed to address the observations comprehensively and within the stipulated time.

You are requested to kindly take the same on record.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**



**Ramanathan Hariharan
Company Secretary & Head- Legal**